NASDAQ:NAMS NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis → Urgent dollar warning (From Stansberry Research) (Ad) Free NAMS Stock Alerts $22.57 +0.60 (+2.73%) (As of 05:13 PM ET) Add Compare Share Share Today's Range$22.02▼$23.0150-Day Range$18.95▼$24.2352-Week Range$5.63▼$26.35Volume136,067 shsAverage Volume233,131 shsMarket Capitalization$2.01 billionP/E RatioN/ADividend YieldN/APrice Target$33.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get NewAmsterdam Pharma alerts: Email Address NewAmsterdam Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside47.3% Upside$33.25 Price TargetShort InterestHealthy0.85% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.08Based on 3 Articles This WeekInsider TradingSelling Shares$4.10 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.89) to ($1.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.00 out of 5 starsMedical Sector368th out of 908 stocksPharmaceutical Preparations Industry163rd out of 419 stocks 3.5 Analyst's Opinion Consensus RatingNewAmsterdam Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNewAmsterdam Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.85% of the float of NewAmsterdam Pharma has been sold short.Short Interest Ratio / Days to CoverNewAmsterdam Pharma has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NewAmsterdam Pharma has recently decreased by 0.80%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldNewAmsterdam Pharma does not currently pay a dividend.Dividend GrowthNewAmsterdam Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NAMS. Previous Next 1.7 News and Social Media Coverage News SentimentNewAmsterdam Pharma has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for NewAmsterdam Pharma this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for NAMS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NewAmsterdam Pharma insiders have sold 1,382.58% more of their company's stock than they have bought. Specifically, they have bought $276,224.00 in company stock and sold $4,095,234.00 in company stock.Percentage Held by InsidersOnly 2.50% of the stock of NewAmsterdam Pharma is held by insiders.Percentage Held by Institutions89.89% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NewAmsterdam Pharma are expected to grow in the coming year, from ($1.89) to ($1.26) per share.Price to Book Value per Share RatioNewAmsterdam Pharma has a P/B Ratio of 6.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchThe Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.Click here to find out for free. About NewAmsterdam Pharma Stock (NASDAQ:NAMS)NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Read More NAMS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NAMS Stock News HeadlinesMay 2, 2024 | finance.yahoo.comNewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024April 30, 2024 | bloomberg.comOzempic Maker Novo Nordisk Has Denmark’s Economy HookedMay 2, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.April 30, 2024 | msn.comFTC challenges ‘junk' patents held by 10 drugmakers, including for Novo Nordisk's OzempicApril 9, 2024 | globenewswire.comNewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular DiseaseApril 9, 2024 | businesswire.comBioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of DirectorsApril 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and NewAmsterdam Pharma Company (NAMS)April 1, 2024 | globenewswire.comNewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business OfficerMay 2, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.March 28, 2024 | msn.comIf you loved NBC's ER, this new Max medical drama is the show for youMarch 25, 2024 | globenewswire.comNewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology CongressMarch 19, 2024 | seekingalpha.comNAMS NewAmsterdam Pharma Company N.V.March 13, 2024 | msn.comAmring Pharmaceuticals Rebrands as Nordic Pharma, Eyes Global Expansion with Strategic AcquisitionMarch 12, 2024 | globenewswire.comNewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVDMarch 1, 2024 | finance.yahoo.comNewAmsterdam Pharma Full Year 2023 Earnings: Revenues Miss ExpectationsFebruary 28, 2024 | finanznachrichten.deNewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 28, 2024 | finance.yahoo.comNewAmsterdam Pharma Co NV (NAMS) Faces Net Loss in 2023 Despite Clinical ProgressFebruary 28, 2024 | globenewswire.comNewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 28, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for NewAmsterdam Pharma with Increased Price Target Amid Promising Drug Trials and Strategic InitiativesFebruary 26, 2024 | finance.yahoo.comNewAmsterdam Pharma to Participate in Upcoming Investor Conferences in MarchFebruary 24, 2024 | msn.comNewAmsterdam Pharma Company N.V. (NAMS) Price Target Increased by 8.93% to 31.11February 23, 2024 | benzinga.comNewAmsterdam Pharma Stock (NASDAQ:NAMS), Insider Trading ActivityFebruary 20, 2024 | msn.comList of Universities that offer pharmacy in South Africa in 2024February 16, 2024 | finanznachrichten.deNewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded WarrantsFebruary 14, 2024 | seekingalpha.comNewAmsterdam Pharma prices $175M share offeringFebruary 14, 2024 | finance.yahoo.comNewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsFebruary 13, 2024 | globenewswire.comNewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsSee More Headlines Receive NAMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/02/2024Next Earnings (Estimated)5/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NAMS CUSIPN/A CIK1936258 Webwww.newamsterdampharma.com Phone352062971FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price Target$33.25 High Stock Price Target$37.00 Low Stock Price Target$30.00 Potential Upside/Downside+51.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.95 Quick Ratio6.95 Sales & Book Value Annual Sales$14.09 million Price / Sales139.20 Cash FlowN/A Price / Cash FlowN/A Book Value$3.50 per share Price / Book6.28Miscellaneous Outstanding Shares89,270,000Free Float87,035,000Market Cap$1.96 billion OptionableOptionable Beta0.08 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Michael Harvey Davidson FACC (Age 68)Facp., M.D., CEO, President, Executive Board Member & Director Comp: $882kDr. Johannes Jacob Pieter Kastelein FESC (Age 70)M.D., Ph.D., Founder, Chief Scientific Officer, Member of Executive Board & Director Comp: $677.76kMr. Mayur Amrat Somaiya (Age 51)Chief Financial Officer Comp: $130.58kMr. Douglas F. Kling (Age 51)Chief Operating Officer Mr. Jim JacobsonChief Legal Officer & SecretaryDr. Marc Ditmarsch M.D. (Age 57)Chief Development Officer Dr. Sheng Cui Ph.D.VP & Head of Chemistry Manufacturing and Controls (CMC)Ms. Annie NeildVP & Head of Regulatory AffairsMr. William Jones Jr. (Age 60)M.B.A., Chief Commercial Officer More ExecutivesKey CompetitorsRocket PharmaceuticalsNASDAQ:RCKTAvidity BiosciencesNASDAQ:RNAAmphastar PharmaceuticalsNASDAQ:AMPHGalapagosNASDAQ:GLPGKeros TherapeuticsNASDAQ:KROSView All CompetitorsInsiders & InstitutionsJennison Associates LLCBought 930,851 shares on 5/2/2024Ownership: 1.043%Yarbrough Capital LLCBought 23,960 shares on 4/10/2024Ownership: 0.027%James N TopperBought 8,429 shares on 3/26/2024Total: $181,223.50 ($21.50/share)Johannes Jacob Piete KasteleinSold 190,476 sharesTotal: $4.10 M ($21.50/share)Fcpm Iii Services B.V.Bought 11,831,461 shares on 3/7/2024Ownership: 14.373%View All Insider TransactionsView All Institutional Transactions NAMS Stock Analysis - Frequently Asked Questions Should I buy or sell NewAmsterdam Pharma stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NewAmsterdam Pharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NAMS shares. View NAMS analyst ratings or view top-rated stocks. What is NewAmsterdam Pharma's stock price target for 2024? 5 analysts have issued 12 month price objectives for NewAmsterdam Pharma's shares. Their NAMS share price targets range from $30.00 to $37.00. On average, they predict the company's stock price to reach $33.25 in the next year. This suggests a possible upside of 47.3% from the stock's current price. View analysts price targets for NAMS or view top-rated stocks among Wall Street analysts. How have NAMS shares performed in 2024? NewAmsterdam Pharma's stock was trading at $11.17 on January 1st, 2024. Since then, NAMS shares have increased by 102.1% and is now trading at $22.57. View the best growth stocks for 2024 here. When is NewAmsterdam Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024. View our NAMS earnings forecast. Who are NewAmsterdam Pharma's major shareholders? NewAmsterdam Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (1.04%) and Yarbrough Capital LLC (0.03%). Insiders that own company stock include James N Topper, Johannes Jacob Piete Kastelein and Louis G Lange. View institutional ownership trends. How do I buy shares of NewAmsterdam Pharma? Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NAMS) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsYour bank is lying to you.MyBankTrackerTrump just won 2024Porter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingA once-in-a-century investment opportunityStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
